Progestogens
Drug Safety Update
September 2019: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping
December 2014: Hormone Replacement Therapy - updated advice before prescribing HRT healthcare professionals should carefully consider the potential benefit and risks for every woman
Local guidance
See here for K&M HRT Prescribing Guideline
NICE Guidance
NG23: Menopause: identification and management
Please note that not all of the progestogen preparations listed below are licensed or on formulary for the following indications:
- Progestogenic opposition of oestrogen HRT
- Prevention of endometrial hyperplasia during oestrogen replacement therapy
Please see the above K&M HRT Prescribing Guideline for progestogen-only HRT preparations which are on formulary for managing menopausal symptoms
| Pack |
|---|
| 30 tablet (3 x 10 tablets) |
| Pack |
|---|
| 10 tablet |
| 100 tablet (10 x 10 tablets) |
| Pack |
|---|
| 10 tablet |
| 100 tablet (10 x 10 tablets) |
| 90 tablet (6 x 15 tablets) |
| Pack |
|---|
| 100 tablet |
| 60 tablet |
Generic micronised progesterone 100mg capsules are first-line over the brand Utrogestan, as this is more cost efficient and in line with national guidance on prescribing medication generically.
| Pack |
|---|
| 30 capsule (2 x 15 capsules) |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary